Transforming growth factor

Biomarker indicative of breast cancer patients' prognosis

Transforming growth factor ([attribution needed], or TGF) is used to describe two classes of polypeptide growth factors, TGFα and TGFβ.

The name "Transforming Growth Factor" is somewhat arbitrary, since the two classes of TGFs are not structurally or genetically related to one another, and they act through different receptor mechanisms. Furthermore, they do not always induce cellular transformation, and are not the only growth factors that induce cellular transformation.

Types

  • TGFα is upregulated in some human cancers. It is produced in macrophages, brain cells, and keratinocytes, and induces epithelial development. It belongs to the EGF family.
  • TGFβ exists in three known subtypes in humans, TGFβ1, TGFβ2, and TGFβ3. These are upregulated in Marfan's syndrome[1][2] and some human cancers, and play crucial roles in tissue regeneration, cell differentiation, embryonic development, and regulation of the immune system.[3][4] Isoforms of transforming growth factor-beta (TGF-β1) are also thought to be involved in the pathogenesis of pre-eclampsia.[5] They belong to the transforming growth factor beta family. TGFβ receptors are single pass serine/threonine kinase receptors.

Function

These proteins were originally characterized by their capacity to induce oncogenic transformation in a specific cell culture system, rat kidney fibroblasts. Application of the transforming growth factors to normal rat kidney fibroblasts induces the cultured cells to proliferate and overgrow, no longer subject to the normal inhibition caused by contact between cells.[6][7]

See also

References

  1. ^ Matt, P; Schoenhoff, F; Habashi, J; Holm, T; Van Erp, C; Loch, D; Carlson, OD; Griswold, BF; Fu, Q; De Backer, J; Loeys, B; Huso, DL; McDonnell, NB; Van Eyk, JE; Dietz, HC (Aug 2009). "Circulating transforming growth factor-{beta} in Marfan syndrome". Circulation. 120 (6): 526–32. doi:10.1161/CIRCULATIONAHA.108.841981. PMC 2779568. PMID 19635970.
  2. ^ "Inhibiting TGF to help Marfan". Archived from the original on 2020-05-29. Retrieved 2008-06-29.
  3. ^ Xu, Xin; Zheng, Liwei; Yuan, Quan; Zhen, Gehua; Crane, Janet L.; Zhou, Xuedong; Cao, Xu (2018-01-31). "Transforming growth factor-β in stem cells and tissue homeostasis". Bone Research. 6: 2. doi:10.1038/s41413-017-0005-4. ISSN 2095-4700. PMC 5802812. PMID 29423331.
  4. ^ Grande, J. P. (1997-01-01). "Role of Transforming Growth Factor- in Tissue Injury and Repair". Experimental Biology and Medicine. 214 (1): 27–40. doi:10.3181/00379727-214-44066. ISSN 1535-3702. PMID 9012358. S2CID 84255552.
  5. ^ Zhang, Jianhong; Dunk, Caroline E.; Shynlova, Oksana; Caniggia, Isabella; Lye, Stephen J. (2018-12-19). "TGFb1 suppresses the activation of distinct dNK subpopulations in preeclampsia". eBioMedicine. 39: 531–539. doi:10.1016/j.ebiom.2018.12.015. ISSN 2352-3964. PMC 6355656. PMID 30579870.
  6. ^ Roberts, A B; Anzano, M A; Lamb, L C; Smith, J M; Sporn, M B (1981). "New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues". Proceedings of the National Academy of Sciences. 78 (9): 5339–5343. Bibcode:1981PNAS...78.5339R. doi:10.1073/pnas.78.9.5339. ISSN 0027-8424. PMC 348740. PMID 6975480.
  7. ^ Strutz, Frank; Zeisberg, Michael; Renziehausen, Anja; Raschke, Birgit; Becker, Volker; Van Kooten, Cees; Müller, Gerhard A. (2001-02-01). "TGF-β1 induces proliferation in human renal fibroblasts via induction of basic fibroblast growth factor (FGF-2)". Kidney International. 59 (2): 579–592. doi:10.1046/j.1523-1755.2001.059002579.x. ISSN 0085-2538. PMID 11168939.

External links

  • Tumor growth factor (TGF) citations
  • Hoffmann, R.; Valencia, A. (2004). "A gene network for navigating the literature". Nature Genetics. 36 (7): 664. doi:10.1038/ng0704-664. PMID 15226743.
  • Transforming+Growth+Factors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)


  • v
  • t
  • e
Angiopoietin
  • Kinase inhibitors: Altiratinib
  • CE-245677
  • Rebastinib
CNTF
EGF (ErbB)
EGF
(ErbB1/HER1)
ErbB2/HER2
  • Agonists: Unknown/none
ErbB3/HER3
ErbB4/HER4
FGF
FGFR1
FGFR2
  • Antibodies: Aprutumab
  • Aprutumab ixadotin
FGFR3
FGFR4
Unsorted
HGF (c-Met)
IGF
IGF-1
  • Kinase inhibitors: BMS-754807
  • Linsitinib
  • NVP-ADW742
  • NVP-AEW541
  • OSl-906
IGF-2
  • Antibodies: Dusigitumab
  • Xentuzumab (against IGF-1 and IGF-2)
Others
  • Cleavage products/derivatives with unknown target: Glypromate (GPE, (1-3)IGF-1)
  • Trofinetide
LNGF (p75NTR)
  • Aptamers: Against NGF: RBM-004
  • Decoy receptors: LEVI-04 (p75NTR-Fc)
PDGF
RET (GFL)
GFRα1
GFRα2
GFRα3
GFRα4
Unsorted
  • Kinase inhibitors: Agerafenib
SCF (c-Kit)
TGFβ
  • See here instead.
Trk
TrkA
  • Negative allosteric modulators: VM-902A
  • Aptamers: Against NGF: RBM-004
  • Decoy receptors: ReN-1820 (TrkAd5)
TrkB
TrkC
VEGF
Others
  • v
  • t
  • e
TGFβ receptor superfamily modulators
Type I
ALK1 (ACVRL1)
  • Kinase inhibitors: K-02288
  • ML-347 (LDN-193719, VU0469381)
  • Other inhibitors: Disitertide
ALK2 (ACVR1A)
  • Kinase inhibitors: DMH-1
  • DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
  • ML-347 (LDN-193719, VU0469381)
ALK3 (BMPR1A)
  • Kinase inhibitors: DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
ALK4 (ACVR1B)
  • Kinase inhibitors: A 83-01
  • SB-431542
  • SB-505124
ALK5 (TGFβR1)
ALK6 (BMPR1B)
  • Kinase inhibitors: DMH-2
  • Dorsomorphin (BML-275)
  • K-02288
ALK7 (ACVR1C)
  • Antagonists: Lefty (1, 2)
  • Kinase inhibitors: A 83-01
  • SB-431542
  • SB-505124
Type II
TGFβR2
  • Kinase inhibitors: DMH-2
  • LY-364947
BMPR2
ACVR2A (ACVR2)
ACVR2B
  • Decoy receptors: Ramatercept
AMHR2 (AMHR)
Type III
TGFβR3 (β-glycan)
Unsorted